Document is current
Any future updates will be listed below
-
Authors
van Os-Medendorp, Harmieke https://orcid.org/0000-0003-3300-2101
Deprez, Elfie https://orcid.org/0000-0001-9660-9192
Maes, Nele
Ryan, Sheila https://orcid.org/0000-0001-9000-6163
Jackson, Karina https://orcid.org/0000-0002-2462-7217
Winders, Tonya https://orcid.org/0000-0001-7689-6438
De Raeve, Linda
De Cuyper, Christa https://orcid.org/0000-0002-5084-7846
Ersser, Steven https://orcid.org/0000-0001-6995-6121
-
Funding
Funding for this research was provided by:
Sanofi Genzyme / Regeneron (NA)
- License Information
-
More Information
Article History
Received: 24 April 2019
Accepted: 20 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: CDC has received payment from GAAPP for coordinating a preparative meeting and honoraria from Novartis for serving as a speaker and as a study investigator (AD studies). HvO has received expense reimbursement from GAAPP for contribution to the meeting and reports grants to her supporting institution (University Medical Center Utrecht) from Sanofi for AD studies. LDR received payment from the GAAPP for lecturing and contributing to the preparative meeting, and received non-financial support from Sanofi-Genzyme.All other authors declare that they have no conflict of interest.
